Progyny (PGNY) to Release Quarterly Earnings on Thursday

Progyny (NASDAQ:PGNY) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.38 per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:45 PM ET.

Progyny Stock Performance

Shares of PGNY stock opened at $20.36 on Thursday. Progyny has a one year low of $17.98 and a one year high of $28.75. The firm’s 50 day moving average price is $24.68 and its 200-day moving average price is $23.21. The firm has a market cap of $1.76 billion, a P/E ratio of 32.32, a P/E/G ratio of 1.29 and a beta of 0.96.

Institutional Investors Weigh In On Progyny

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Progyny during the fourth quarter worth $25,000. Canada Pension Plan Investment Board acquired a new stake in shares of Progyny during the 2nd quarter worth about $77,000. Quarry LP lifted its stake in Progyny by 2,004.1% during the third quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after purchasing an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Progyny by 203.5% in the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock valued at $154,000 after purchasing an additional 4,708 shares in the last quarter. Finally, Entropy Technologies LP acquired a new stake in Progyny during the fourth quarter worth approximately $203,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PGNY shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. BTIG Research reiterated a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Finally, Canaccord Genuity Group raised their price target on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.80.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.